Cargando…

Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy

Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. F...

Descripción completa

Detalles Bibliográficos
Autores principales: Käsmann, Lukas, Eze, Chukwuka, Taugner, Julian, Roengvoraphoj, Olarn, Dantes, Maurice, Schmidt-Hegemann, Nina-Sophie, Schiopu, Sanziana, Belka, Claus, Manapov, Farkhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350600/
https://www.ncbi.nlm.nih.gov/pubmed/32646443
http://dx.doi.org/10.1186/s13014-020-01595-3
_version_ 1783557300418510848
author Käsmann, Lukas
Eze, Chukwuka
Taugner, Julian
Roengvoraphoj, Olarn
Dantes, Maurice
Schmidt-Hegemann, Nina-Sophie
Schiopu, Sanziana
Belka, Claus
Manapov, Farkhad
author_facet Käsmann, Lukas
Eze, Chukwuka
Taugner, Julian
Roengvoraphoj, Olarn
Dantes, Maurice
Schmidt-Hegemann, Nina-Sophie
Schiopu, Sanziana
Belka, Claus
Manapov, Farkhad
author_sort Käsmann, Lukas
collection PubMed
description Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC.
format Online
Article
Text
id pubmed-7350600
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73506002020-07-14 Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy Käsmann, Lukas Eze, Chukwuka Taugner, Julian Roengvoraphoj, Olarn Dantes, Maurice Schmidt-Hegemann, Nina-Sophie Schiopu, Sanziana Belka, Claus Manapov, Farkhad Radiat Oncol Review Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer treatment. Preclinical studies investigating combination of ICI with radiation show a synergistic improvement of tumor control probability and have resulted in the development of novel therapeutic strategies. For advanced non-small cell lung cancer (NSCLC), targeting immune checkpoint pathways has proven to be less toxic with more durable treatment response than conventional chemotherapy. In inoperable Stage III NSCLC, consolidation immune checkpoint inhibition with the PD-L1 inhibitor durvalumab after completion of concurrent platinum-based chemoradiotherapy resulted in remarkable improvement of progression-free and overall survival. This new tri-modal therapy has become a new treatment standard. Development of predictive biomarkers and improvement of patient selection and monitoring is the next step in order to identify patients most likely to derive maximal benefit from this new multimodal approach. In this review, we discuss the immunological rationale and current trials investigating chemoradioimmunotherapy for inoperable stage III NSCLC. BioMed Central 2020-07-09 /pmc/articles/PMC7350600/ /pubmed/32646443 http://dx.doi.org/10.1186/s13014-020-01595-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Käsmann, Lukas
Eze, Chukwuka
Taugner, Julian
Roengvoraphoj, Olarn
Dantes, Maurice
Schmidt-Hegemann, Nina-Sophie
Schiopu, Sanziana
Belka, Claus
Manapov, Farkhad
Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
title Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
title_full Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
title_fullStr Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
title_full_unstemmed Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
title_short Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
title_sort chemoradioimmunotherapy of inoperable stage iii non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350600/
https://www.ncbi.nlm.nih.gov/pubmed/32646443
http://dx.doi.org/10.1186/s13014-020-01595-3
work_keys_str_mv AT kasmannlukas chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT ezechukwuka chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT taugnerjulian chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT roengvoraphojolarn chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT dantesmaurice chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT schmidthegemannninasophie chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT schiopusanziana chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT belkaclaus chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy
AT manapovfarkhad chemoradioimmunotherapyofinoperablestageiiinonsmallcelllungcancerimmunologicalrationaleandcurrentclinicaltrialsestablishinganovelmultimodalstrategy